1-10639015-C-T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The ENST00000377022.8(CASZ1):c.5207G>A(p.Arg1736Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000178 in 998,624 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
ENST00000377022.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CASZ1 | NM_001079843.3 | c.5207G>A | p.Arg1736Gln | missense_variant | 21/21 | ENST00000377022.8 | NP_001073312.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CASZ1 | ENST00000377022.8 | c.5207G>A | p.Arg1736Gln | missense_variant | 21/21 | 1 | NM_001079843.3 | ENSP00000366221 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000857 AC: 125AN: 145858Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000990 AC: 1AN: 10104Hom.: 0 AF XY: 0.000159 AC XY: 1AN XY: 6308
GnomAD4 exome AF: 0.0000622 AC: 53AN: 852726Hom.: 1 Cov.: 32 AF XY: 0.0000579 AC XY: 23AN XY: 396934
GnomAD4 genome AF: 0.000857 AC: 125AN: 145898Hom.: 0 Cov.: 32 AF XY: 0.000803 AC XY: 57AN XY: 70968
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 31, 2021 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. This variant has not been reported in the literature in individuals affected with CASZ1-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1736 of the CASZ1 protein (p.Arg1736Gln). - |
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 29, 2021 | The c.5207G>A (p.R1736Q) alteration is located in exon 21 (coding exon 18) of the CASZ1 gene. This alteration results from a G to A substitution at nucleotide position 5207, causing the arginine (R) at amino acid position 1736 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at